Tamoxifen (Nolvadex) - Selective Estrogen Receptor Modulator — Anabolic Steroids
First-generation SERM FDA-approved since 1977 for breast cancer treatment and prevention, and a cornerstone of post-cycle therapy (PCT) for HPTA recovery after anabolic steroid use.
Overview
Tamoxifen (Nolvadex) is a selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in breast tissue and an estrogen agonist in bone and uterus. FDA-approved in 1977, it is one of the most extensively studied anti-cancer drugs in history. The NSABP P-1 trial (n=13,388) demonstrated a 49% reduction in breast cancer incidence in high-risk women (RR 0.51, p<0.00001). The STAR trial (n=19,747) compared tamoxifen to raloxifene, finding similar breast cancer risk reduction. In the bodybuilding and hormone optimization community, tamoxifen is a cornerstone of post-cycle therapy (PCT) due to its ability to stimulate hypothalamic-pituitary-gonadal axis recovery by blocking estrogen negative feedback at the hypothalamus and pituitary, increasing LH and FSH secretion. Tamoxifen also directly protects against gynecomastia by competitively blocking estrogen receptors in breast glandular tissue. It has a long half-life (5-7 days) and active metabolites (4-hydroxytamoxifen, endoxifen) that contribute to its clinical effects. PMID: 9747868, 16495393, 14569039.
Indications
- Adjuvant treatment of HR+ breast cancer in pre- and postmenopausal women (FDA-approved; EBCTCG meta-analysis)
- Breast cancer risk reduction in high-risk women (FDA-approved; NSABP P-1 trial)
- Post-cycle therapy (PCT) for HPTA recovery after anabolic steroid use (off-label, widely practiced)
- Gynecomastia prevention and treatment during aromatizing steroid cycles (off-label)
- Male infertility associated with hypogonadotropic hypogonadism (off-label)
Mechanism of Action
Tamoxifen competitively binds estrogen receptors (ER-α and ER-β) with tissue-specific effects: antagonist in breast, agonist in bone and uterus, mixed in liver and brain
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Tamoxifen (Nolvadex) | 20 mg | Once daily | Standard dose for breast cancer treatment and prevention; also standard PCT dose |
| Tamoxifen | 40 mg | Once daily for first 2 weeks of PCT | Aggressive PCT loading dose; followed by 20mg/day for remaining 2-4 weeks |
| Tamoxifen | 10 mg | Once daily | Low-dose for gynecomastia prevention during mild cycles; or maintenance after PCT |
| Tamoxifen | 20 mg | Once daily for 5-10 years | Breast cancer adjuvant therapy; ATLAS trial showed 10 years superior to 5 years |
Safety & Contraindications
- Increased risk of endometrial cancer (2-7x; estrogen agonist effect on uterus): annual gynecological assessment in women; report abnormal vaginal bleeding immediately
- Venous thromboembolism risk: 2-3x increased risk of DVT/PE; higher risk with concurrent oral contraceptives or HRT
- Hot flashes (up to 80% of patients), night sweats, and mood disturbances are common
- Ocular toxicity: rare reports of retinopathy, corneal changes, and cataracts with long-term use (>5 years); ophthalmologic exam if visual symptoms
- CYP2D6 polymorphisms affect metabolism to active metabolite endoxifen: poor metabolizers may have reduced efficacy; avoid strong CYP2D6 inhibitors (fluoxetine, paroxetine)
- In males, generally well-tolerated; rare hepatotoxicity; estrogen agonist effect on bone is beneficial